Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions.
Jones
S G
SG
Dolan
G
G
Lengyel
K
K
Myers
B
B
D000368:Aged; D003404:Creatinine / Q000652:urine*; D004164:Diphosphonates / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006996:Hypocalcemia / Q000139:chemically induced* / Q000652:urine; D007093:Imidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000652:urine; D013792:Thalidomide / Q000627:therapeutic use*; D000077211:Zoledronic Acid
D004164:Diphosphonates; D007093:Imidazoles; D007166:Immunosuppressive Agents; D013792:Thalidomide; D000077211:Zoledronic Acid; D003404:Creatinine